Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-1

[News]

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.

More... (http://www.news-medical.net/news/20150728/Research-brief-describes-enrollment-of-first-patient-with-TRK-fusion-cancer-in-LOXO-101-Phase-1-trial.aspx)